Vitrectomy Versus Observation for Lamellar Macular Holes With Epiretinal Proliferation: A Systematic Review and Meta-Analysis.

Am J OphthalmolJun 1, 2026 (epub)
Clinical ResearchOphthalmology

Luís Expedito Sabage, João Victor Cunha Miranda, Ana Beatriz Ferreira DO Amaral Antunes et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the visual and anatomical outcomes of vitrectomy versus observation in patients with lamellar macular holes and epiretinal proliferation. Among 610 eyes, vitrectomy resulted in a significant visual improvement (pooled mean difference in BCVA -0.170 logMAR; P < .001), while no significant change was observed in the observational group. The risk of progression to full-thickness macular hole was similar between groups.

Key findings

  • Vitrectomy led to a significant visual improvement with a pooled mean difference in BCVA of -0.170 logMAR (P < .001).
  • No significant change in visual acuity was observed in the observational cohort (-0.029 logMAR; P = .695).
  • The pooled rate of progression to full-thickness macular hole was 7.5% after vitrectomy and 4.2% after observation.

Why it matters

Understanding the outcomes of vitrectomy versus observation for lamellar macular holes with epiretinal proliferation is crucial for informed patient counseling and treatment planning, especially given the potential for visual improvement with surgery.

Source

PubMed · PMID 42229561

Published in Am J Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.